Dopamine midbrain neurons in health and Parkinson’s disease: Emerging roles of voltage-gated calcium channels and ATP-sensitive potassium channels
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Dopamine (DA) releasing midbrain neurons are essential for multiple brain functions, such as voluntary movement, working memory, emotion and cognition. DA midbrain neurons within the substantia nigra (SN) and the ventral tegmental area (VTA) exhibit a variety of distinct axonal projections and cellular properties, and are differentially affected in diseases like schizophrenia, attention deficit hyperactivity disorder, and Parkinson's disease (PD). Apart from having diverse functions in health and disease states, DA midbrain neurons display distinct electrical activity patterns, crucial for DA release. These activity patterns are generated and modulated by specific sets of ion channels. Recently, two ion channels have been identified, not only contributing to these activity patterns and to functional properties of DA midbrain neurons, but also seem to render SN DA neurons particularly vulnerable to degeneration in PD and its animal models: L-type calcium channels (LTCCs) and ATP-sensitive potassium channels (K-ATPs). In this review, we focus on the emerging physiological and pathophysiological roles of these two ion channels (and their complex interplay with other ion channels), particularly in highly vulnerable SN DA neurons, as selective degeneration of these neurons causes the major motor symptoms of PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
How mitochondria produce reactive oxygen species
Murphy, M. P. (2009) · Biochemical Journal · doi:10.1042/bj20081386 · Cited by 8,207
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
The physiology, signaling, and pharmacology of dopamine receptors
Beaulieu, J.-M., & Gainetdinov, R. R. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002642 · Cited by 2,763 · cited 1×
“NCS-1/D2-R interaction prevents D2-R desensitization by preventing G protein-coupled receptor kinase 2 (GRK2)-mediated phosphorylation of D2-R and thus b-arrestin-mediated receptor-internalization (Beaulieu and Gainetdinov, 2011; Kabbani et al., 2012).”
Stages in the development of Parkinson’s disease-related pathology
Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H., & Del Tredici, K. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0956-9 · Cited by 2,689 · cited 2×
“…addiction, attention deficit hyperactivity disorder (ADHD) and Parkinson's disease (PD), the second most common neurodegenerative disease (Braak et al., 2004; Bjorklund and Dunnett, 2007; Dagher and Robbins, 2009; Stuber et al., 2010; Shulman et al., 2011; Bari and Robbins, 2013; Russo…”
Dopamine in motivational control: rewarding, aversive, and alerting
Bromberg-Martin, E. S., Matsumoto, M., & Hikosaka, O. (2010) · Neuron · doi:10.1016/j.neuron.2010.11.022 · Cited by 2,396
Cocaine Receptors on Dopamine Transporters Are Related to Self-Administration of Cocaine
Ritz, M. C., Lamb, R. J., Goldberg, S. R., & Kuhar, M. J. (1987) · Science · doi:10.1126/science.2820058 · Cited by 2,180
Neuroinflammation in Parkinson’s disease: A target for neuroprotection?
Hirsch, E. C., & Hunot, S. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70062-6 · Cited by 1,984
By Carrot or by Stick: Cognitive Reinforcement Learning in Parkinsonism
Frank, M. J., Seeberger, L. C., & O'Reilly, R. C. (2004) · Science · doi:10.1126/science.1102941 · Cited by 1,964
Inhibition and impulsivity: behavioral and neural basis of response control
Bari, A., & Robbins, T. W. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.06.005 · Cited by 1,921
The brain reward circuitry in mood disorders
Russo, S. J., & Nestler, E. J. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3381 · Cited by 1,870 · cited 2×
“…and Parkinson's disease (PD), the second most common neurodegenerative disease (Braak et al., 2004; Bjorklund and Dunnett, 2007; Dagher and Robbins, 2009; Stuber et al., 2010; Shulman et al., 2011; Bari and Robbins, 2013; Russo and Nestler, 2013; Sulzer and Surmeier, 2013; Brisch et al., 2014).”
The action potential in mammalian central neurons
Bean, B. P. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2148 · Cited by 1,785 · cited 3×
“…SN DA neurons predominantly display an intrinsically generated, regular, so-called pacemaker activity, with relatively low frequency ($0.5–3 Hz) (Bean, 2007a; Ford and Williams, 2008; Lammel et al., 2008; Margolis et al., 2010; Drion et al., 2011; Ungless and Grace, 2012; Branch et al., 2014).”
InfluentialDopamine neuron systems in the brain: An update
Björklund, A., & Dunnett, S. B. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.006 · Cited by 1,777 · cited 4×
“Important in this context is that DA midbrain neurons are not equally affected by the degenerative process in PD, with SN DA neurons being particularly vulnerable to PD-trigger factors (as specified below), compared to more resistant neighboring VTA DA neurons (Bjorklund and Dunnett, 2007; Schultz, 2010b).”
InfluentialBalleine, B. W., & O'Doherty, J. P. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.131 · Cited by 1,775
Bender, A., Krishnan, K. J., Morris, C. M., Taylor, G. A., Reeve, A. K., Perry, R. H., Jaros, E., Hersheson, J. S., Betts, J., Klopstock, T., et al. (2006) · Nature Genetics · doi:10.1038/ng1769 · Cited by 1,570 · cited 2×
“In essence, activity-related cellular Ca load, mitochondrial DNA deletions and mitochondrial dysfunction, as well as oxidative and metabolic stress are particularly important trigger factors for PD (Bender et al., 2006; Guzman et al., 2010; Alves da Costa and Checler, 2011; Collier et al., 2011; Shulman et al., 2011;…”
Multiple dopamine functions at different time courses
Schultz, W. (2007) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.28.061604.135722 · Cited by 1,415 · cited 2×
“…in response to novel, unexpected or salient events, and encodes so-called ''Go'' signals facilitating movement initiation and motor learning and reward prediction (Chase et al., 2004; Schultz, 2007; Bromberg- Martin et al., 2010; Jin and Costa, 2010; Costa, 2011; Morikawa and Paladini, 2011).”
Role of calcium ions in regulation of mammalian intramitochondrial metabolism
McCormack, J. G., Halestrap, A. P., & Denton, R. M. (1990) · Physiological Reviews · doi:10.1152/physrev.1990.70.2.391 · Cited by 1,398 · cited 2×
“enzymes of the tricarboxylic acid cycle (TCA), calcium can increase activity of the electron transfer chain (ETC) – and thus increase generation of ROS and metabolic stress (McCormack et al., 1990; Sanchez-Padilla et al., 2014).”
Telomere dysfunction induces metabolic and mitochondrial compromise
Sahin, E., Colla, S., Liesa, M., Moslehi, J., Müller, F. L., Guo, M., Cooper, M., Kotton, D., Fabian, A. J., Walkey, C., et al. (2011) · Nature · doi:10.1038/nature09787 · Cited by 1,319 · cited 2×
“It is very likely that a similar mechanism is also present in SN DA neurons, thereby contributing to compromised mitochondrial and bioenergetic function (Kelly, 2011; Sahin et al., 2011; Exner et al., 2012), rendering them more vulnerable to PD-trigger factors and degeneration.”
Input-specific control of reward and aversion in the ventral tegmental area
Lammel, S., Lim, B. K., Ran, C., Huang, K. W., Betley, M. J., Tye, K. M., Deisseroth, K., & Malenka, R. C. (2012) · Nature · doi:10.1038/nature11527 · Cited by 1,300 · cited 2×
“…axonal projections to e.g. limbic and cortical areas, play central roles in cognition, motivation, addiction, reward and aversive behavior (Margolis et al., 2010; Stuber et al., 2010; Bourdy and Barrot, 2012; Lammel et al., 2012; Ungless and Grace, 2012; Luscher, 2013; Roeper, 2013; Lammel, 2014).”
Goal-directed and habitual control in the basal ganglia: implications for Parkinson's disease
Redgrave, P., Rodriguez, M., Smith, Y., Rodriguez-Oroz, M. C., Lehericy, S., Bergman, H., Agid, Y., DeLong, M. R., & Obeso, J. A. (2010) · Nature reviews. Neuroscience · doi:10.1038/nrn2915 · Cited by 1,134 · cited 4×
“…learning, habit formation, goal-directed action selection and exploration (Chase et al., 2004; Balleine and O'Doherty, 2009; Jin and Costa, 2010; Redgrave et al., 2010; Costa, 2011; Schiemann et al., 2012; Everitt and Robbins, 2013) while neighboring VTA DA neurons, with axonal projections to…”
InfluentialGlucose induces closure of single potassium channels in isolated rat pancreatic β-cells
Ashcroft, F. M., Harrison, D. E., & Ashcroft, S. J. H. (1984) · Nature · doi:10.1038/312446a0 · Cited by 1,113 · cited 1×
“K-ATP channels have first been described in pancreatic ß-cells, where their closure in response to rising blood glucose levels – and concomitantly increased intracellular ATP levels – is triggering insulin secretion (Ashcroft et al., 1984; Nichols, 2006; Clark and Proks, 2010; Seino, 2012).”
Regulation of firing of dopaminergic neurons and control of goal-directed behaviors
Grace, A. A., Floresco, S. B., Goto, Y., & Lodge, D. J. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.003 · Cited by 1,034 · cited 2×
“…movement and goal-directed behavior, as well as cognition, emotion, reward, motivation, working memory, associative learning and decision making (Grace et al., 2007; Redgrave et al., 2010; Schultz, 2010a; Gerfen and Surmeier, 2011; Salimpoor et al., 2011; D'Ardenne et al., 2012; Chowdhury et…”
Unique properties of mesoprefrontal neurons within a dual mesocorticolimbic dopamine system
Lammel, S., Hetzel, A., Häckel, O., Jones, I., Liss, B., & Roeper, J. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.022 · Cited by 976
Self-citationReward and aversion in a heterogeneous midbrain dopamine system
Lammel, S., Lim, B. K., & Malenka, R. C. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.03.019 · Cited by 804
Parkinson’s disease: genetics and pathogenesis
Shulman, J. M., De Jager, P. L., & Feany, M. B. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130242 · Cited by 801 · cited 6×
“Accordingly, dysfunctions of the DA midbrain system are associated with neurological and psychiatric diseases, such as schizophrenia, addiction, attention deficit hyperactivity disorder (ADHD) and Parkinson’s disease (PD), the second most common neurodegenerative disease (Braak et al., 2004; Bjorklund and Dunnett, 200…”
InfluentialFrom the ventral to the dorsal striatum: devolving views of their roles in drug addiction
Everitt, B. J., & Robbins, T. W. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.02.010 · Cited by 675
Dopamine signals for reward value and risk: basic and recent data
Schultz, W. (2010) · Behavioral and Brain Functions · doi:10.1186/1744-9081-6-24 · Cited by 653 · cited 3×
“The majority of DA midbrain neurons are located in two overlapping nuclei, the substantia nigra (SN, A9) and the ventral tegmental area (VTA, A10) (Schultz, 2010b).”
Lüscher, C., & Slesinger, P. A. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2834 · Cited by 617 · cited 1×
“2) (Luscher and Slesinger, 2010).”
Insulin activates ATP-sensitive K+ channels in hypothalamic neurons of lean, but not obese rats
Spanswick, D., Smith, M. A., Mirshamsi, S., Routh, V. H., & Ashford, M. L. J. (2000) · Nature Neuroscience · doi:10.1038/77660 · Cited by 495 · cited 2×
“insulin, leptin, ghrelin, long-chain fatty-acids (acyl-CoA), PIP2, pH, hydrogen peroxide and NO (Spanswick et al., 2000; Levin et al., 2004; Lin et al., 2004; Avshalumov et al., 2007; Haider et al., 2007; Andrews et al., 2009; Leinninger et al., 2009; Opland et al., 2010; Fioramonti et al., 2011; Levin et al., 2011; R…”
Type 2 Diabetes and the Risk of Parkinson's Disease
Hu, G., Jousilahti, P., Bidel, S., Antikainen, R., & Tuomilehto, J. (2007) · Diabetes Care · doi:10.2337/dc06-2011 · Cited by 466
Zweifel, L. S., Parker, J. G., Lobb, C. J., Rainwater, A., Wall, V. Z., Fadok, J. P., Darvas, M., Kim, M. J., Mizumori, S. J. Y., Paladini, C. A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813415106 · Cited by 426 · cited 2×
“…DA neurons, projecting to the dorsomedial striatum, K-ATP channel activity facilitates the switch from tonic firing to NMDA glutamate receptor (NMDA-R)-mediated burst activity in vivo (Johnson et al., 1992; Johnson and Wu, 2004; Deister et al., 2009; Zweifel et al., 2009; Schiemann et al., 2012).”
Leinninger, G. M., Jo, Y.-H., Leshan, R. L., Louis, G. W., Yang, H., Barrera, J. G., Wilson, H., Opland, D. M., Faouzi, M. A., Gong, Y., et al. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.06.011 · Cited by 412 · cited 1×
“…fatty-acids (acyl-CoA), PIP 2 , pH, hydrogen peroxide and NO (Spanswick et al., 2000; Levin et al., 2004; Lin et al., 2004; Avshalumov et al., 2007; Haider et al., 2007; Andrews et al., 2009; Leinninger et al., 2009; Opland et al., 2010; Fioramonti et al., 2011; Levin et al., 2011; Rice, 2011).”
Andrews, Z. B., Erion, D., Beiler, R., Liu, Z.-W., Abizaid, A., Zigman, J., Elsworth, J. D., Savitt, J. M., DiMarchi, R., Tschöp, M., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3890-09.2009 · Cited by 289
KATP channels and islet hormone secretion: new insights and controversies
Ashcroft, F. M., & Rorsman, P. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.166 · Cited by 272 · cited 6×
“…in SN DA neurons might provide another novel neuroprotective strategy for PD. Pharmacological K-ATP channel blockers (like glibenclamide) are – similar to LTCC blockers – already well-established and widely used drugs to treat type 2 diabetes (T2D) (Ashcroft, 2007; Ashcroft and Rorsman, 2013).”
InfluentialHuman substantia nigra neurons encode unexpected financial rewards
Zaghloul, K. A., Blanco, J. A., Weidemann, C. T., McGill, K., Jaggi, J. L., Baltuch, G. H., & Kahana, M. J. (2009) · Science · doi:10.1126/science.1167342 · Cited by 264
Khaliq, Z. M., & Bean, B. P. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.0143-10.2010 · Cited by 261 · cited 1×
“1B, and reviewed in detail elsewhere (Chan et al., 2007; Khaliq and Bean, 2010; Liss & Roeper, 2010; Margolis et al., 2010; Surmeier et al., 2012; Ungless and Grace, 2012; Dufour et al., 2014).”
Surmeier, D. J., Guzman, J. N., Sanchez-Padilla, J., & Schumacker, P. T. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.08.045 · Cited by 236 · cited 6×
“Contribution of LTCCs in SN DA neurons to PD pathology LTCC activity and related calcium signaling however comes at a high price, since it burdens SN DA neurons with an oscillatory calcium load, associated with their electrical activity (Guzman et al., 2010; Surmeier et al., 2011).”
InfluentialKrebs, R. M., Heipertz, D., Schuetze, H., & Duzel, E. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.06.038 · Cited by 135 · cited 1×
“Consistent with these findings in rodents, recent human functional brain imaging data revealed that a corresponding rostromedial part of the medial SN/VTA midbrain complex in humans is indeed strongly and selectively activated by novel, but non-rewarding stimuli (Krebs et al., 2011).”
Modulation of the mesolimbic dopamine system by leptin
Opland, D. M., Leinninger, G. M., & Myers (2010) · Brain Research · doi:10.1016/j.brainres.2010.04.028 · Cited by 111
ATP-sensitive K + channels and disease: from molecule to malady
Ashcroft, F. M. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00348.2007 · Cited by 107 · cited 7×
“…in SN DA neurons might provide another novel neuroprotective strategy for PD. Pharmacological K-ATP channel blockers (like glibenclamide) are – similar to LTCC blockers – already well-established and widely used drugs to treat type 2 diabetes (T2D) (Ashcroft, 2007; Ashcroft and Rorsman, 2013).”
InfluentialKanno, T., Rorsman, P., & Göpel, S. O. (2002) · The Journal of Physiology · doi:10.1113/jphysiol.2002.031344 · Cited by 89 · cited 2×
“…channels are pharmacologically blocked by sulfonylureas such as glibenclamide or tolbutamide (Amoroso et al., 1990; Gomis and Valdeolmillos, 1998; Kanno et al., 2002; Bryan et al., 2005; Ashcroft, 2007), and their activity is physiologically regulated by a variety of metabolic signals, such as…”
Multiple functions of dopamine neurons
Schultz, W. (2010) · F1000 Biology Reports · doi:10.3410/b2-2 · Cited by 59 · cited 3×
“The majority of DA midbrain neurons are located in two overlapping nuclei, the substantia nigra (SN, A9) and the ventral tegmental area (VTA, A10) (Schultz, 2010b).”
Cited by
Selective neuronal vulnerability in Parkinson disease
Surmeier, D. J., Obeso, J. A., & Halliday, G. M. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.178 · Cited by 1,116
Determinants of dopaminergic neuron loss in Parkinson's disease
Surmeier, D. J. (2018) · The FEBS Journal · doi:10.1111/febs.14607 · Cited by 444
Purinergic Signalling: Therapeutic Developments
Burnstock, G. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00661 · Cited by 398
Toll, L., Bruchas, M. R., Calo', G., Cox, B. M., & Zaveri, N. T. (2016) · Pharmacological Reviews · doi:10.1124/pr.114.009209 · Cited by 297
Calcium and Parkinson's disease
Surmeier, D. J., Schumacker, P. T., Guzman, J. D., Ilijic, E., Yang, B., & Zampese, E. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.08.168 · Cited by 202
“In principle, this feed-forward control of OXPHOS helps to ensure that bioenergetic needs are met [68,69,70,71] and that intracellular ATP levels do not fall into a range that would trigger protective activation of K-ATP channels, which would cause cessation of on-going activity [72].”
Background
Metadata
- Authors
- Dragicevic, E., Schiemann, J., & Liss, B.
- Venue
- Neuroscience
- Publisher
- Elsevier BV
- Published
- 2015-01
- Volume
- 284
- Pages
- 798-814
- ISSN
- 0306-4522 (ISSN-L)
- OpenAlex
- W2051841169
- Cited by
- 136
- References
- 41
- FWCI
- 9.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.